Cargando…
Rethinking Radical Surgery in Interval Debulking Surgery for Advanced-Stage Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy
The aim of this study is to evaluate the effects on survival outcomes of the disease burden before interval debulking surgery (IDS), surgical complexity, and residual disease after IDS in advanced-stage ovarian cancer treated with neoadjuvant chemotherapy (NAC). We reviewed the data of 268 epithelia...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231092/ https://www.ncbi.nlm.nih.gov/pubmed/32344611 http://dx.doi.org/10.3390/jcm9041235 |
_version_ | 1783535111029915648 |
---|---|
author | Lee, Yong Jae Lee, Jung-Yun Nam, Eun Ji Kim, Sang Wun Kim, Sunghoon Kim, Young Tae |
author_facet | Lee, Yong Jae Lee, Jung-Yun Nam, Eun Ji Kim, Sang Wun Kim, Sunghoon Kim, Young Tae |
author_sort | Lee, Yong Jae |
collection | PubMed |
description | The aim of this study is to evaluate the effects on survival outcomes of the disease burden before interval debulking surgery (IDS), surgical complexity, and residual disease after IDS in advanced-stage ovarian cancer treated with neoadjuvant chemotherapy (NAC). We reviewed the data of 268 epithelial ovarian cancer patients who had received three or four cycles of NAC and undergone optimal resections through IDS. The Kaplan–Meier method and Cox regression analysis were used to assess the effects of disease burden (peritoneal cancer index (PCI)), degree of complexity of surgery (surgical complexity score/s (SCS)), and extent of residual disease. In no residual disease (R0) patients, those with intermediate/high SCS had shorter progression-free survival (PFS; p = 0.001) and overall survival (OS; p = 0.001) than patients with low SCS. An analysis of a subset of patients with R0 and low PCIs showed those with intermediate/high SCS had worse PFS and OS than patients with low SCS (p = 0.049) and OS (p = 0.037). In multivariate analysis, patients with R0 as a result of intermediate/high SCS fared worse than patients whose R0 was achieved by low SCS (PFS hazard ratio (HR) 1.80, 95% CI 1.05–3.10; OS HR 5.59, 95% CI 1.70–18.39). High PCIs at the time of IDS, high SCS, and residual disease signal poor prognoses for patients treated with NAC. |
format | Online Article Text |
id | pubmed-7231092 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-72310922020-05-22 Rethinking Radical Surgery in Interval Debulking Surgery for Advanced-Stage Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy Lee, Yong Jae Lee, Jung-Yun Nam, Eun Ji Kim, Sang Wun Kim, Sunghoon Kim, Young Tae J Clin Med Article The aim of this study is to evaluate the effects on survival outcomes of the disease burden before interval debulking surgery (IDS), surgical complexity, and residual disease after IDS in advanced-stage ovarian cancer treated with neoadjuvant chemotherapy (NAC). We reviewed the data of 268 epithelial ovarian cancer patients who had received three or four cycles of NAC and undergone optimal resections through IDS. The Kaplan–Meier method and Cox regression analysis were used to assess the effects of disease burden (peritoneal cancer index (PCI)), degree of complexity of surgery (surgical complexity score/s (SCS)), and extent of residual disease. In no residual disease (R0) patients, those with intermediate/high SCS had shorter progression-free survival (PFS; p = 0.001) and overall survival (OS; p = 0.001) than patients with low SCS. An analysis of a subset of patients with R0 and low PCIs showed those with intermediate/high SCS had worse PFS and OS than patients with low SCS (p = 0.049) and OS (p = 0.037). In multivariate analysis, patients with R0 as a result of intermediate/high SCS fared worse than patients whose R0 was achieved by low SCS (PFS hazard ratio (HR) 1.80, 95% CI 1.05–3.10; OS HR 5.59, 95% CI 1.70–18.39). High PCIs at the time of IDS, high SCS, and residual disease signal poor prognoses for patients treated with NAC. MDPI 2020-04-24 /pmc/articles/PMC7231092/ /pubmed/32344611 http://dx.doi.org/10.3390/jcm9041235 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Lee, Yong Jae Lee, Jung-Yun Nam, Eun Ji Kim, Sang Wun Kim, Sunghoon Kim, Young Tae Rethinking Radical Surgery in Interval Debulking Surgery for Advanced-Stage Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy |
title | Rethinking Radical Surgery in Interval Debulking Surgery for Advanced-Stage Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy |
title_full | Rethinking Radical Surgery in Interval Debulking Surgery for Advanced-Stage Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy |
title_fullStr | Rethinking Radical Surgery in Interval Debulking Surgery for Advanced-Stage Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy |
title_full_unstemmed | Rethinking Radical Surgery in Interval Debulking Surgery for Advanced-Stage Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy |
title_short | Rethinking Radical Surgery in Interval Debulking Surgery for Advanced-Stage Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy |
title_sort | rethinking radical surgery in interval debulking surgery for advanced-stage ovarian cancer patients undergoing neoadjuvant chemotherapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231092/ https://www.ncbi.nlm.nih.gov/pubmed/32344611 http://dx.doi.org/10.3390/jcm9041235 |
work_keys_str_mv | AT leeyongjae rethinkingradicalsurgeryinintervaldebulkingsurgeryforadvancedstageovariancancerpatientsundergoingneoadjuvantchemotherapy AT leejungyun rethinkingradicalsurgeryinintervaldebulkingsurgeryforadvancedstageovariancancerpatientsundergoingneoadjuvantchemotherapy AT nameunji rethinkingradicalsurgeryinintervaldebulkingsurgeryforadvancedstageovariancancerpatientsundergoingneoadjuvantchemotherapy AT kimsangwun rethinkingradicalsurgeryinintervaldebulkingsurgeryforadvancedstageovariancancerpatientsundergoingneoadjuvantchemotherapy AT kimsunghoon rethinkingradicalsurgeryinintervaldebulkingsurgeryforadvancedstageovariancancerpatientsundergoingneoadjuvantchemotherapy AT kimyoungtae rethinkingradicalsurgeryinintervaldebulkingsurgeryforadvancedstageovariancancerpatientsundergoingneoadjuvantchemotherapy |